Skip to main content

Advertisement

SpringerLink
Log in

Evolving treatment approaches for early breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Treatment approaches for early breast cancer continue to evolve as key trials involving adjuvant chemotherapy and hormonal therapy provide results that can inform clinical practice. The administration of a taxane, either in combination with or following doxorubicin and cyclophosphamide, has been shown to significantly improve disease-free survival (DFS) and overall survival (OS). In addition, a dose-dense treatment approach (reducing the inter-treatment interval) was found to be more effective than conventionally scheduled treatment in terms of DFS and OS. As treatment schemes evolve, supportive care becomes increasingly important to manage the toxicities of chemotherapy, such as anemia and impaired cognition. In addition to chemotherapy, the use of hormonal therapy continues to evolve, with studies demonstrating the benefit of the aromatase inhibitors and serum estrogen receptor down-regulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • InstitutionalAuthorNameEarly Breast Cancer Trialists’ Collaborative Group (1998) ArticleTitlePolychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930–942

    Google Scholar 

  • InstitutionalAuthorNameEarly Breast Cancer Trialists’ Collaborative Group (1998) ArticleTitleTamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1451–1467

    Google Scholar 

  • A Goldhirsch WC Wood RD Gelber AS Coates B Thürlimann HJ Senn (2003) ArticleTitleMeeting highlights: updated international expert consensus on the primary therapy of early breast cancer J Clin Oncol 21 3357–3365 Occurrence Handle10.1200/JCO.2003.04.576 Occurrence Handle12847142

    Article  PubMed  Google Scholar 

  • RW Blamey (2002) ArticleTitleGuidelines on endocrine therapy of breast cancer EUSOMA Eur J Cancer 38 615–634 Occurrence Handle11916542 Occurrence Handle1:STN:280:DC%2BD387osVektQ%3D%3D

    PubMed  CAS  Google Scholar 

  • National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Breast cancer. Version 3: 2003

  • BF Cole RD Gelber S Gelber AS Coates A Goldhirsch (2001) ArticleTitlePolychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis Lancet 358 277–286 Occurrence Handle11498214 Occurrence Handle1:CAS:528:DC%2BD3MXlslCjsLs%3D

    PubMed  CAS  Google Scholar 

  • IC Henderson DA Berry GD Demetri CT Cirrincione LJ Goldstein S Martino JN Ingle MR Cooper DF Hayes KH Tkaczuk G Fleming JF Holland DB Duggan JT Carpenter E Frei SuffixIII RL Schilsky WC Wood HB Muss L Norton (2003) ArticleTitleImproved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976–983 Occurrence Handle12637460 Occurrence Handle1:CAS:528:DC%2BD2cXpsVGqs7c%3D

    PubMed  CAS  Google Scholar 

  • EP Mamounas J Bryant BC Lembersky B Fisher JN Atkins L Fehrenbacher PC Raich G Yothers A Soran N Wolmark (2003) ArticleTitlePaclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc Am Soc Clin Oncol 22 4

    Google Scholar 

  • Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, Raich PC, Yothers G, Soran A, Wolmark N: Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Presentation at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, May 31–June 3, 2003

  • JM Nabholtz T Pienkowski J Mackey M Pawlicki JP Guastalla C Vogel C Weaver B Walley M Martin L Chap E Tomiak E Juhos R Guevin A Howell J Hainsworth T Fornander S Blitz S Gazel C Loret A Riva (2002) ArticleTitlePhase III trial comparing TAC (docetaxel, doxorubicin cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21 36a

    Google Scholar 

  • Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Hugh J, Nabholtz JM, Loret C, Rupin M, Blitz S, Riva A, Vogel C, On behalf of the BCIRG 001 Investigators: TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. In: 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 3–6, 2003 (abstract 43)

  • K Boér I Láng E Juhos T Pintér J Szántó (2003) ArticleTitleHungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial Magy Onkol 47 141–148 Occurrence Handle12975660

    PubMed  Google Scholar 

  • ML Citron DA Berry C Cirrincione C Hudis EP Winer WJ Gradishar NE Davidson S Martino R Livingston JN Ingle EA Perez J Carpenter D Hurd JF Holland BL Smith CI Sartor EH Leung J Abrams RL Schilsky HB Muss L Norton (2003) ArticleTitleRandomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 1431–1439 Occurrence Handle10.1200/JCO.2003.09.081 Occurrence Handle12668651 Occurrence Handle1:CAS:528:DC%2BD2cXptlCks7s%3D

    Article  PubMed  CAS  Google Scholar 

  • Moebus V, Kurbacher C, Nitz U, Untch M, Eidtmann H, duBois A, Kuhn W, Lueck H-J, Thomssen C, Jackisch C: Epoetin alpha prevents anemia and transfusions in patients (pts) receiving dose-dense sequential chemotherapy (ETC). In: 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 3–6, 2003 (abstract 638)

  • JC Egrie JK Browne (2001) ArticleTitleDevelopment and characterization of novel erythropoiesis stimulating protein (NESP) Nephrol Dial Transplant 16 IssueIDSuppl 3 3–13 Occurrence Handle11402085

    PubMed  Google Scholar 

  • IC Macdougall (2002) ArticleTitleOptimizing the use of erythropoietic agents – pharmacokinetic and pharmacodynamic considerations Nephrol Dial Transplant 17 IssueIDSuppl 5 66–70 Occurrence Handle12091611 Occurrence Handle1:CAS:528:DC%2BD38XmsFagurc%3D

    PubMed  CAS  Google Scholar 

  • U Denison J Baumann C Peters-Engl H Samonigg P Krippl A Lang A Obermair H Wagner P Sevelda (2003) ArticleTitleIncidence of anaemia in breast cancer patients receiving adjuvant chemotherapy Breast Cancer Res Treat 79 347–353 Occurrence Handle12846419 Occurrence Handle1:CAS:528:DC%2BD3sXktlagsr4%3D

    PubMed  CAS  Google Scholar 

  • J Kirshner M Hatch DD Hennessy M Fridman RE Tannous (2004) ArticleTitleAnemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy Oncologist 9 25–32 Occurrence Handle14755012 Occurrence Handle1:CAS:528:DC%2BD2cXhs1Smt7g%3D

    PubMed  CAS  Google Scholar 

  • GD Lawless JM Ford (2004) ArticleTitleCumulative prevalence of anemia in early-stage breast cancer (ESBC) patients Blood 96 390b

    Google Scholar 

  • JA O’ Shaughnessy (2002) ArticleTitleEffects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy Clin Breast Cancer 3 IssueIDSuppl 3 S116–S120 Occurrence Handle10.3816/CBC.2002.s.022 Occurrence Handle1:CAS:528:DC%2BD3sXhtVCktrg%3D

    Article  CAS  Google Scholar 

  • D Greene LM Nail VK Fieler D Dudgeon LS Jones (1994) ArticleTitleA comparison of patient-reported side effects among three chemotherapy regimens for breast cancer Cancer Pract 2 57–62 Occurrence Handle8055007 Occurrence Handle1:STN:280:ByuA3s3hsl0%3D

    PubMed  CAS  Google Scholar 

  • JA Broeckel PB Jacobsen J Horton L Balducci GH Lyman (1998) ArticleTitleCharacteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer J Clin Oncol 16 1689–1696 Occurrence Handle9586880 Occurrence Handle1:STN:280:DyaK1c3ks1aqsA%3D%3D

    PubMed  CAS  Google Scholar 

  • TA Ahles AJ Saykin CT Furstenberg B Cole LA Mott K Skalla MB Whedon S Bivens T Mitchell ER Greenberg PM Silberfarb (2002) ArticleTitleNeuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma J Clin Oncol 20 485–493 Occurrence Handle11786578 Occurrence Handle1:CAS:528:DC%2BD38XovVKhsA%3D%3D

    PubMed  CAS  Google Scholar 

  • FS Dam Particlevan SB Schagen MJ Muller W Boogerd E Wall ME Droogleever Fortuyn S Rodenhuis (1998) ArticleTitleImpairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy J Natl Cancer Inst 90 210–218 Occurrence Handle9462678

    PubMed  Google Scholar 

  • SB Schagen MJ Muller W Boogerd RM Rosenbrand D Rhijn Particlevan S Rodenhuis FS Dam Particlevan (2002) ArticleTitleLate effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients Ann Oncol 13 1387–1397 Occurrence Handle12196364 Occurrence Handle1:STN:280:DC%2BD38vjvVGjtQ%3D%3D

    PubMed  CAS  Google Scholar 

  • Jacobsen PB, Thors CL, Cawley M, Ax E, Grendys ECJ: Relation of decline in hemoglobin to cognitive functioning and fatigue during chemotherapy treatment. In: 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, USA, May 18–21, 2002 (abstract 1542)

  • N Tchen HG Juffs FP Downie QL Yi H Hu I Chemerynsky M Clemons M Crump PE Goss D Warr ME Tweedale IF Tannock (2003) ArticleTitleCognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer J Clin Oncol 21 4175–4183 Occurrence Handle10.1200/JCO.2003.01.119 Occurrence Handle14615445

    Article  PubMed  Google Scholar 

  • O’Shaughnessy J, Vukelja S, Savin M, Holmes FA, Jones M, Royall D, George M, von Hoff D: Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data. In: 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 11–14, 2002 (poster 530)

  • Hudis CA, Williams D, Gralow JR, and the Procrit® Study Group: Epoetin alfa maintains hemoglobin levels and quality of life in breast cancer patients during conventional adjuvant chemotherapy. In: 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 11–14, 2002 (poster 539)

  • Hudis CA, Williams D: Early treatment of mild anemia with once-weekly epoetin alfa significantly improves hemoglobin and quality of life in early-stage breast cancer patients during conventional adjuvant chemotherapy. In: 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 3–6, 2003 (poster 639)

  • InstitutionalAuthorNameThe ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists’ Group (2002) ArticleTitleAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131–2139

    Google Scholar 

  • InstitutionalAuthorNameThe ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists’ Group (2003) ArticleTitleAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 1802–1810

    Google Scholar 

  • PE Goss JN Ingle S Martino NJ Robert HB Muss MJ Piccart M Castiglione D Tu LE Shepherd KI Pritchard RB Livingston NE Davidson L Norton EA Perez JS Abrams P Therasse MJ Palmer JL Pater (2003) ArticleTitleA randomized trial of letrozole in␣postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1793–1802 Occurrence Handle10.1056/NEJMoa032312 Occurrence Handle1:CAS:528:DC%2BD3sXptFGnsbk%3D Occurrence Handle14551341

    Article  CAS  PubMed  Google Scholar 

  • Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Massobrio M, Benedetto C, Porpiglia M, Rinaldini M, Paladini G, Distante V, Franchi R, Failla G, Bordonaro R, Sismondi P: Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. In: 26th Annual San Antonio Breast Cancer Symposium December 3–6, 2003 (abstract 3)

  • RC Coombes E Hall LJ Gibson R Paridaens J Jassem T Delozier SE Jones I Alvarez G Bertelli O Ortmann AS Coates E Bajetta D Dodwell RE Coleman LJ Fallowfield E Mickiewicz J Andersen PE Lonning G Cocconi A Stewart N Stuart CF Snowdon M Carpentieri G Massimini JM Bliss (2004) ArticleTitleA randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081–1092 Occurrence Handle15014181 Occurrence Handle1:CAS:528:DC%2BD2cXitV2qtbc%3D

    PubMed  CAS  Google Scholar 

  • V Shilling V Jenkins L Fallowfield T Howell (2003) ArticleTitleThe effects of hormone therapy on cognition in breast cancer J Steroid Biochem Mol Biol 86 405–412 Occurrence Handle14623538 Occurrence Handle1:CAS:528:DC%2BD3sXptVemsL0%3D

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA

    Susana M. Campos

Authors
  1. Susana M. Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susana M. Campos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campos, S.M. Evolving treatment approaches for early breast cancer. Breast Cancer Res Treat 89 (Suppl 1), S1–S7 (2005). https://doi.org/10.1007/s10549-005-0142-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-005-0142-0

Key words

Search

Navigation